Ocaliva In NASH Manageable With Indication-Based Pricing, ICER Roundtable Suggests

Indication-specific pricing could address 'tension' between initial pricing of Ocaliva for orphan condition and later use in large patient population, according to expert roundtable convened by Institute for Clinical and Economic Review.